Pharnext SCA

OTC:PNEXF

Dr. Daniel E. Cohen is a distinguished medical professional known for his work in the field of biopharmaceuticals. He co-founded Pharnext SCA, a clinical-stage biopharmaceutical company that focuses on developing therapies for neurodegenerative diseases. Holding both an M.D. and a Ph.D., Dr. Cohen has an extensive background in biotechnology and pharmaceuticals. Under his leadership, Pharnext has pioneered the R&D approach called "PLEOTHERAPY™," which aims to identify synergistic combinations of repositioned drugs. Besides his role at Pharnext, Dr. Cohen has been instrumental in founding several other biopharmaceutical companies, making significant contributions to medical research and innovation. His work is characterized by a deep commitment to advancing treatment options for patients with unmet medical needs in neurology. His expertise and vision have driven forward the strategic direction of Pharnext, enabling it to become a key player in its field.

Hugo Brugière is a prominent figure in the biotechnology and finance sectors, known for his leadership and innovative approach. He serves as the CEO of Pharnext SCA, a biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases. Under his leadership, Pharnext has been committed to advancing its research and development programs, particularly its flagship pleotherapy platform, which aims to repurpose existing drugs for new therapeutic applications in complex diseases. Brugière's background is diverse, encompassing both scientific and financial expertise. He holds a Master of Science degree, which has informed his analytical and strategic thinking in guiding Pharnext's growth and development. Before joining Pharnext, Hugo Brugière had extensive experience in investment banking and fund management, where he honed skills in corporate finance and strategic business development. His career is marked by an ability to bridge scientific innovation and commercial viability, aiming to enhance Pharnext's position in the competitive biotech industry while seeking to address unmet medical needs. His leadership is characterized by a strong vision for the future of transformative medicines and a commitment to driving shareholder value through strategic partnerships and innovative research.

Ilya Chumakov is a prominent figure in the field of biotechnology and pharmacology, known for his work with Pharnext SCA, a biopharmaceutical company that focuses on the development of innovative therapies for neurodegenerative diseases and other severe chronic disorders. With both a Doctor of Science (D-Sc) and a Doctor of Philosophy (Ph.D.), Chumakov has a strong academic background that underpins his research and leadership in the industry. At Pharnext, Chumakov has been instrumental in advancing the company's scientific research and development efforts. His work often involves the application of network pharmacology, which aims to discover synergistic combinations of drugs that can effectively treat complex diseases. This approach is at the core of Pharnext's R&D strategy and has led to the development of novel drug candidates. Chumakov's contributions are not only limited to technical expertise; he is also recognized for his ability to lead teams and foster collaborations within the scientific community. His role at Pharnext encompasses overseeing research projects, guiding strategic planning, and ensuring that the company's objectives align with the latest scientific developments. Moreover, Chumakov's research has been published in numerous scientific journals, reflecting his status as a respected figure in his field. Through his efforts, Pharnext continues to hone its focus on addressing unmet medical needs, especially in the domain of rare and complex diseases.

Vincent Serra, Ph.D., is a respected figure in the field of biotechnology and pharmaceuticals, and he is associated with Pharnext SCA, a biopharmaceutical company focused on developing treatments for severe neurodegenerative diseases. Dr. Serra serves as the Chief Scientific Officer (CSO) of Pharnext, where he plays a critical role in guiding the scientific strategy and research efforts of the company. With a strong background in pharmacology and neurodegenerative disease research, Dr. Serra has contributed to advancing Pharnext's innovative approach to drug discovery and development. Pharnext utilizes a unique platform called Pleotherapy, which focuses on drug combinations that leverage genomic and pharmacological data to create novel therapies. Before joining Pharnext, Vincent Serra gained extensive experience in the pharmaceutical industry, holding various research and leadership positions. His expertise spans across multiple therapeutic areas, including central nervous system disorders, and he has been involved in the successful development of several drug candidates. Throughout his career, Dr. Serra has published numerous scientific papers and has been active in both academic and industry circles, contributing to significant advancements in medical science. His work at Pharnext continues to be pivotal as the company focuses on addressing unmet medical needs with innovative treatments.

Gilbert Wagener, M.D., Ph.D., was a prominent figure at Pharnext SCA, serving as the Chief Medical Officer. With an extensive background in medical research and development, Dr. Wagener played a crucial role in advancing the company's clinical development programs. He brought a wealth of experience in pharmaceuticals, having worked across various therapeutic areas and contributing significantly to the strategic direction of medical and scientific projects. His expertise was instrumental in guiding Pharnext's efforts to innovate and deliver new treatments, particularly in the realm of neurodegenerative diseases. Dr. Wagener's leadership and vision were key assets to Pharnext's mission to improve patient outcomes through groundbreaking therapies.